Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

BACKGROUND: Only a minority of patients with advanced non-small cell lung cancer (NSCLC) benefit from chemotherapy. Serum peptide profiling of NSCLC patients was performed to investigate patterns associated with treatment outcome. Using magnetic bead-assisted serum peptide capture coupled to matrix-...

Descripción completa

Detalles Bibliográficos
Autores principales: Voortman, Johannes, Pham, Thang V, Knol, Jaco C, Giaccone, Giuseppe, Jimenez, Connie R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746186/
https://www.ncbi.nlm.nih.gov/pubmed/19728888
http://dx.doi.org/10.1186/1477-5956-7-34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746186/
https://www.ncbi.nlm.nih.gov/pubmed/19728888
http://dx.doi.org/10.1186/1477-5956-7-34

Ejemplares similares